Skip to content

Bio-Rad Laboratories, Inc.

BIO· NYSECore metricsCIK 12208

Laboratory analytical instruments24 peers

Last sale
Nov 12, 2026 · -3.96%
Market cap
$9.60B
26.89M shares
Filings
1,030
$656.40M
Q3 2026+0.7% FY25 yoy
$458.60M
Q3 2026N/M FY25 yoy
-$49.70M
Q3 2026−82.5% FY25 yoy
$210.00M
Q3 2026derived+29.4% FY25 yoy
$17.02
Q3 2026N/M FY25 yoy
$465.30M
Q3 2026+8.5% FY25 yoy
$9.60B
9.4×
3.7×
1.3×
3.43%
—

Twelve months to Sep 30, 2026 · derived

Price

$370.66+18.13%+$56.89past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$2.58BFY 2025
$2.92B0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$2,583,200,000reported
FY 20242024-12-31$2,566,500,000reported
FY 20232023-12-31$2,671,200,000 revisedreported
FY 20222022-12-31$2,802,200,000reported
FY 20212021-12-31$2,922,500,000reported
FY 20202020-12-31$2,545,600,000reported
FY 20192019-12-31$2,311,700,000reported
FY 20182018-12-31$2,289,400,000reported
FY 20172017-12-31$2,160,200,000reported
FY 20162016-12-31$2,068,200,000reported
FY 20152015-12-31$2,019,441,000reported
FY 20142014-12-31$2,175,044,000reported

Capital returns

Dividends and buybacks · FY2016 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$295.50M$295.50M———78.9%
FY2024—$203.60M$203.60M———70.3%
FY2023—$428.70M$428.70M———196.5%
FY2022—$215.70M$215.70M———264.3%
FY2021—$50.00M$50.00M———9.3%

Segments

Revenue by Segments, FY2018 to FY2023FY2018Clinical Diagnostics · FY2018 · $1.41BLife Science · FY2018 · $861.70MAll Other Segments · FY2018 · $15.90MFY2019Clinical Diagnostics · FY2019 · $1.41BLife Science · FY2019 · $885.90MAll Other Segments · FY2019 · $13.80MFY2020Clinical Diagnostics · FY2020 · $1.31BLife Science · FY2020 · $1.23BAll Other Segments · FY2020 · $8.60MFY2021Clinical Diagnostics · FY2021 · $1.52BLife Science · FY2021 · $1.40BAll Other Segments · FY2021 · $5.80MFY2022Clinical Diagnostics · FY2022 · $1.45BLife Science · FY2022 · $1.35BAll Other Segments · FY2022 · $4.00MFY2023Clinical Diagnostics · FY2023 · $1.49BLife Science · FY2023 · $1.18BAll Other Segments · FY2023 · $3.60M
LineFY2023ShareChange
Clinical Diagnostics$1.49B56%+2.6%
Life Science$1.18B44%−12.5%
All Other Segments$3.60M0.1%−10.0%
Total$2.67B

From the 10-K filed Feb 16, 2024BIO

Laboratory analytical instruments

Bio-Rad Laboratories, Inc. is the 8th largest of the 25 covered companies the SEC files under this code, by revenue. SIC 3826

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR